Rocket Pharmaceuticals (RCKT) Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for Treatment of Danon Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| (NASDAQ: RCKT) | Delayed: 2.28 -0.01 (0.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.29 | 52 Week High | $ | |||
| Open | $2.29 | 52 Week Low | $ | |||
| Day High | $2.29 | P/E | N/A | |||
| Day Low | $2.22 | EPS | $ | |||
| Volume | 1,514,758 | |||||
